Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
May 7, 2024
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, everyone, and thanks for being with us on this call covering our Q1 2024 results and business update. Here with me are two of my colleagues: Lisa Delfini, who serves as Trevi's Chief Financial Officer, and Dr. David Clark, Trevi's Chief Medical Officer. It was only 6 weeks back that we shared our Q4 earnings. Lisa and I will therefore keep our remarks short, and afterward the 3 of us would be glad to take your questions. Things are quite busy right now at Trevi as we push forward with clinical development for refractory chronic cough, or RCC, and also for cough tied to idiopathic pulmonary fibrosis, or IPF. Let me give you a quick rundown on our studies, starting with the Phase IIa RCC trial, for which we anticipate data later in 2024. RCC is a debilitating condition impacting as much as 10% of adults, characterized by a cough that persists beyond 8 weeks even when the underlying condition is treated. Since no therapies have won approval for RCC in the U.S., a major and pressing need remains for novel treatment options. What sets Haduvio apart in RCC is how it works — its mechanism of action acts synergistically in the brain centrally and in the lungs peripherally. In our view, that mechanism could help a larger share of patients and may deliver a more pronounced benefit across a wider spectrum of baseline cough counts compared with peripherally acting mechanisms alone, such as the P2X3 inhibitors. Our RCC study, called RIVER, is a Phase IIa, double-blind, randomized, placebo-controlled, 2-period crossover trial assessing cough reduction in roughly 60 patients. The design mirrors other Phase IIa cough studies conducted so far, though it adds one important distinction. Randomization will be stratified 1:1 between patients coughing 10 to 19 times per hour and those coughing more than 20 times per hour. Every treatment period runs 3 weeks, with a 3-week washout in between. For those receiving Haduvio, the dose gets titrated each week, starting at 27 milligrams and reaching 108 milligrams twice daily over the dosing period. Relative change in 24-hour cough frequency, captured through an objective cough monitor, serves as the primary efficacy endpoint. Secondary endpoints will also be explored, among them patient-reported measures of cough and quality of life. All 14 sites are now up and running for this trial, and among enrolled subjects we're seeing a nearly even split between the two arms — the 10 to 19 and the greater than 20 cough counts. Enrollment continues to move forward, and our expectation remains top line data during the second half of this year. Now, an update on our lead program for IPF chronic cough. IPF is a severe end-of-life disease. Roughly 85% of individuals with IPF experience chronic cough, and its physical, psychological, and social consequences are comparable in severity to those of RCC. Beyond that, it might act as a risk factor contributing to progression of the underlying IPF disease. Ongoing lung damage, microtears, and possible inflammation triggered by continual coughing could result in poorer outcomes for patients, including more respiratory-related hospital admissions, death, or the requirement for a transplant. Since no approved therapies exist today for chronic cough in IPF, both patients and clinicians face a pressing demand for new treatment options. Although numerous development programs for IPF are underway, neither available nor investigational therapies have demonstrated any effect on chronic cough, which ranks among the hardest elements of IPF to manage, thereby heightening the unmet need. Our CORAL trial is a Phase IIb, parallel-arm, dose-ranging study examining 3 active doses of Haduvio alongside placebo. This 6-week study involves roughly 160 patients. We're running it across multiple countries and sites so that enrollment can be finished promptly. We anticipate that most of our planned 60 sites will be activated by the close of June. Enrollment is moving forward, and we're collaborating with our sites to keep our study a priority. We restate our guidance for this trial: results from our sample size reestimation analysis should read out during the second half of this year, and we still anticipate top line data from the full study in the first half of 2025. As a reminder, the SSRE takes place once 50% of subjects have completed the study; we plan to share those SSRE results upon completion, and they will either confirm our existing study sizing assumptions, recommend upsizing within a prespecified range, or indicate utility. We've likewise achieved solid enrollment progress on our human abuse potential study, or half, this year; that study is now about 75% enrolled, and we expect enrollment to wrap up this summer. This study aims to establish the abuse potential of oral nalbuphine compared with butorphanol and placebo, and it was designed and agreed upon with input from the FDA. Recall that parenteral nalbuphine is unscheduled by the DEA and was recently rereviewed by the DEA and left on schedule. It's also worth noting that the 2 parts of nalbuphine's mechanism are unscheduled as well, whether a kappa agonist like Korsuva or mu antagonists in products such as naloxone and naltrexone; this study will be submitted alongside our NDA as part of an 8-factor plan, which encompasses all preclinical work done to date, the mechanistic rationale for why this drug is unscheduled, our clinical data generated in our development programs, the results of this HAP study, as well as a public health rationale. We're aiming for oral nalbuphine ER to stay unscheduled, just like the parenteral version has been for all these years; likewise, we still anticipate receiving top line data from this trial during the latter half of this year. And lastly, the FDA has cleared our IND for IPF cough, and we plan to launch our respiratory physiology study in Q3 of 2024; our expectation is that this study will take place in both the U.S. and the U.K. This trial's objective is to methodically gauge how nalbuphine ER affects respiratory depression across differing degrees of disease severity in IPF, so we can pin down our Phase III patient population. Up until now, sleep disorder breathing patients have been left out of our studies, and going forward we want to gain a clearer picture of safety within that group. As you can tell, things are clinically hectic right now at Trevi, and we feel the results from these trials will matter a great deal in shaping the development path ahead for Haduvio across chronic cough conditions. We're eager to start wrapping up these studies in the back half of this year and to report the findings. One last thing — over the coming months, our management team will be at a number of medical conferences, among them the American Thoracic Society meeting in San Diego in two weeks, the London Cough Conference in July, and the European Respiratory Society Meeting in Austria in September. If you're planning to go, please tell us, since we'd really enjoy connecting with you. I'll hand things over now to Lisa for a look at our financial results, and after that we'll take any questions.
Lisa Delfini
executiveThanks, Jennifer, and good afternoon to all of you. You can find the complete financial results for the 3 months that ended March 31, 2024, in the press release we put out before this call, as well as in our 10-Q, which was filed with the SEC today once the market closed. Finance had a quiet first quarter of 2024, since the rest of the company is focused operationally on enrolling and executing the 4 trials Jennifer talked about today. During the first quarter of 2024, our net loss came in at $10.9 million, versus a net loss of $6.4 million in the same quarter of 2023. R&D expenses reached $8.8 million in the first quarter of 2024, up from $5 million in the comparable quarter of '23, largely because of higher clinical development expenses for our Phase IIb CORAL trial, our Phase IIa RIVER trial and our HAP trial. Those increases were partly offset by lower clinical development expenses for our Phase IIb/III PRISM trial. G&A expenses came to $3.1 million in the first quarter of 2024, versus $2.6 million in the same period of 2023, mainly driven by growth in information technology and finance staffing and activities, along with professional fees. Other income net was $1 million in the first quarter of 2024, compared with $1.2 million in the same period of 2023. As of March 31, 2024, cash, cash equivalents and marketable securities came to a total of $72.8 million, compared with $83 million as of December 31, 2023. We used roughly $10.9 million in cash during Q1 '24, offset by approximately $700,000 of interest received. That falls within the range of our expected cash burn for the year of $9 million to $12 million per quarter. Our cash runway guidance is still unchanged, and we have cash, cash equivalents and marketable securities into 2026. That wraps up our prepared remarks, and I'll now hand the call back to the operator for Q&A.
Leland Gershell
analystOnly a couple of items from me. To start, regarding the ATS meeting that's coming up, we're eager — I think we'll get a cough bout analysis from CANAL presented by Dr. Jacky Smith out of the U.K. Ahead of that data, Jennifer, could you perhaps walk us through how a cough bout is formally defined, at least in this context? And how much do cough bouts affect IPF patients? Then I have another question.
Jennifer Good
executiveSure, that works. I'll set it up, and then I'll hand it to David for the details, since he was heavily involved in the paper. The thing is, this entire idea of cough bouts strikes me as quite similar to itch, in that when we discuss average cough, it's kind of averaged across time. Yet there's a sense that when patients experience these intense bouts, that's where a great deal of the harm occurs; so interest is growing in examining how that appears. Sadly, the field hasn't reached consensus on what constitutes a cough bout, which is partly what the discussion is about. And 2 very prominent KOLs have used our data to run the analysis. So Dr. Smith will present that, and I'll have David describe precisely her methodology at this meeting. Then I believe in the fall, another of the KOLs will present it with a different methodology; but David, could you walk through Jacky's methodology and how it's going to be presented?
David Clark
executiveOf course I can. Dr. Smith's preferred approach treats a coughing fit as starting with a minimum of 2 coughs, after which an off period must occur. That off period exists so that a bout counts as continuing whenever a cough arrives — normally the off period lasts 2 seconds, meaning any cough happening inside those 2 seconds keeps that bout going. In an exploratory manner, she also likes examining off periods for cough bouts ranging from 1 second up to 10 seconds. Consequently, what the paper shows involves examining how this cough bout gets defined. Thus, coughs falling within that span, which ranges between 1 and 10 seconds, are included. Regarding such a cough bout definition, as Jennifer Good noted, the field lacks full agreement, yet the approach Dr. Smith applies is likely among the more widespread cough bout definitions; and afterward we have — as we mentioned, another methodology of ours will be shared later in the year.
Leland Gershell
analystThen I'd like to ask about the HAP study. I understand you're evaluating several doses there, and it's clearly encouraging to hear about the recent FDA support for no scheduling of nalbuphine. If significant liking showed up at, I suppose, any of those dose levels, would that add to concerns that we might see some type of DEA scheduling? How much sensitivity is there — in any way you could quantify it for us — to the scheduling risk tied to the HAP study?
Jennifer Good
executiveYes; so the scheduling decision is going to be made. It starts as a review decision by the division, which then gets deferred to the DEA. They do consider what you might call, Gershell, that 8-factor analysis. So the drug's mechanism, whatever epidemiology tells them about it, what appeared in your own clinical trials — there's basically a large overall picture they take into account. Now the HAP is not in — the preclinical data matters a great deal too, and all of that has been completed, and all of it is clean. The HAP, however, is not insignificant. My view is it isn't that you can see nothing in your data; in theory, you're going to be somewhat more likable than placebo. If you turn out to be considerably more likable than butorphanol, that starts the conversation. I think it will simply depend; we'll need to examine that data in the context of everything else. I will say, though, that when I sat through the initial discussions of what the FDA focuses on, it isn't that you can't have any signs of this. What truly worries them is a dose response in likability. So if you get some likability at, say, your low dose, and that doubles, then triples with your high dose — that's where problems arise, because they obviously fear people taking your tablets, and that's an issue; so it's a difficult question to answer, Leland. And internally, we've been wrestling with it. I think once we have the data, we'll present it as clearly as we can and have an expert join the call so people can interrogate the data themselves and pose the questions.
Jack Padovano
analystJack Padovano here, filling in for Annabel. So once you get to that sample size reestimation in IPF, what are the odds the trial has already reached statistical significance by then? And should that happen, would you simply keep going as planned through the final readout? Or is there a possibility you'd stop the study early in that scenario? Then, as a follow-up to that: thinking back on how large the effect was that we've already observed in IPF, if effects of that kind hold up in the trials coming up, do you see any chance to go directly from POC into Phase 3?
Jennifer Good
executiveSo David, both of those are yours to answer.
David Clark
executiveYeah. So when it comes to the SSRE we're using, regulators—especially the FDA—won't accept success criteria of the kind you just described. So say you've got 80 subjects who've finished the primary time point, and you've got separation from placebo at a number of doses. The FDA isn't going to let you write that kind of success criteria into a standard SSRE like this; so that answers your first question. It's really just, in a closed loop system, you're asking whether your variance and your effect size are enough for the assumptions you're bringing in. So your sample size can't go below 160; and what was your second question? I apologize.
Jennifer Good
executiveOn that second one, David, I can start us off, and then you can chime in with more detail. What he was asking is whether the size of the effect is large. Is it possible to move directly from POC into pivotals? My view is that in IPF, we're running a Phase IIb aimed at picking the dose, and the plan is to transition into our pivotal program. As for RIVER, the Phase IIa, the way the internal team sees it — and David, this is a spot where you can add some color — is that we intend to run a Phase IIb designed to resemble a pivotal. So we'll likely still need to carry out some dose ranging work to be sure we're clear in that patient group, but we'll try to shape it so it resembles a pivotal study, and then based on what the data show, we can hopefully hold discussions; but David, is there any color you'd like to add there?
David Clark
executiveNo, I think that addresses it very well. Thanks, Jennifer.
Nathanael Charoensook
analystNat Charoensook here, filling in for Thomas Smith. We've got a few things to ask about the RIVER study; so to start, why was a 21-day duration selected, given that endpoint assessment in the other late-phase trials happens at 12 or 24 weeks? And I have one more question after that.
Jennifer Good
executiveYes. What I'd say is the reasoning comes from all the Phase II2s — I mean, regarding the compounds you're seeing in development right now, every one of them used this Phase IIa crossover design as a proof-of-concept, more or less to demonstrate your drug is doing its job, and it removes some variability. Once you're past proof-of-concept, that's the point where you move into trials of longer length.
Nathanael Charoensook
analystUnderstood. And regarding 2024, what are you anticipating from the data? When you examine the shift in cough frequency instead of absolute changes, do you expect a distinct degree of efficacy in patients whose cough frequency is moderate compared with those whose cough frequency is severe?
Jennifer Good
executiveDavid, would you like to say a few words about the hypothesis behind the study and what we hope to demonstrate across the various cough levels and such?
David Clark
executiveAbsolutely, Jennifer, I can do that. So here's what we know at this point — and as you're aware, this comes solely from the CANAL study, in the IPF chronic cough population — and that is that the efficacy signal was not affected by cough frequency at baseline. Regardless of that cough frequency, it remained just as robust in the subjects. So that's all the information we have as we head into this; and as you know, peripheral-based mechanisms of action have had trouble getting the signal in that moderate population. But what we're going into the study with is that, based on the IPF chronic cough, we saw no evidence of a difference — a change tied to baseline cough frequency.
Nathanael Charoensook
analystGot it. Also, are you intending to incorporate efficacy endpoints capable of capturing things such as cough cluster or cough episodes, which seem to burden patients with RCC?
David Clark
executiveI apologize — could you say that question again?
Jennifer Good
executiveIs that the clustering of coughs you're referring to? And are we collecting any of that information?
Nathanael Charoensook
analystYeah.
Jennifer Good
executiveYeah. And David, I believe we're in a position to revisit that and get the analysis right.
David Clark
executiveYes, of course — we've defined that analysis in advance, and we're going to run it, since, as we've said previously, our view is that the main endpoint for cough programs will remain unchanged from what it is today, relying on cough frequency over 24 hours. That said, these cough bouts, under those various definitions, do carry clinical significance. Consequently, across every study we conduct from here on, we genuinely want to examine them, so that we grasp the kinds of effects we're producing on that front, alongside what we expect will serve as the registration endpoint.
Mayank Mamtani
analystNice work on the advances. So perhaps regarding the SSRE for the CORAL study. Could you possibly spell out the statistical assumption for placebo and, I suppose, the highest dose you intend to demonstrate separation against. Maybe just the number of patients, the effect size, and the p-value. Also, is there anything in the baseline characteristics that might differ between CORAL and CANAL that we ought to know about? Then I have one quick follow-up.
Jennifer Good
executiveDavid, would you like to handle that?
David Clark
executiveAbsolutely, Jennifer — regarding the inclusion criteria, nothing was altered. The method we're using to choose the IPF chronic cough population matches what we applied in CANAL. The key distinction, as you're aware, is that this is a worldwide study, so there could be some variation there. We'll find out during the trial. As for the assumptions behind the SSRE, the enrollment target of 160 — that works out to 40 in each arm. This is predicated on an effect size for the active drug over placebo, layered on top of the placebo response. In other words, a separation above placebo response of 36%. With 160 enrolled, 40 per arm, we have in excess of 80% power entering the study. The maximum sample size permitted, we stated at 160 — we're able to increase to 400. That applies if either the variance turns out higher than anticipated or the effect size comes in smaller. To illustrate, should the effect size require raising to that maximum of 400 — which is 100 per arm — if that becomes necessary, it would let us detect a clinically relevant effect size of 25% above placebo. That's the reasoning behind how we characterized the SSRE.
Mayank Mamtani
analystReally useful. Next, regarding the Phase II RIVER study's moderate and severe cohorts, is enrollment divided evenly between them? Also, would you plan to share data during the second half for each cohort separately, or instead do one combined pooled analysis? Finally, what format will the presentation for this half study take? Of course, it's encouraging to see enrollment at 75%, yet the follow-up period is fairly brief. So I'm wondering whether that would be a press release, an event, or a KOL event. Could you make that clear?
Jennifer Good
executiveThanks, Mayank. Enrollment in RIVER is going well so far; we're observing roughly balanced numbers across moderate and severe. Naturally, we won't complete the study until everyone is enrolled. We will — we intend to include that in our top line data. So it won't be disclosed afterward. It will be included when we report our top line data. Regarding the format for human abuse potential, we're still figuring that out; but my sense is that we're aiming for a press release, plus hosting a call with likely 1 or 2 experts on the line who deal with this area routinely. So we'll share the data from our side, and then open the call so people like you can pose any questions you have about the data. I mean, ideally it's straightforward and there isn't much to debate, but that's also positive and gives you all a chance to verify that for yourselves. So that's the plan we're currently pursuing.
Jennifer Good
executiveThanks. When it comes to our clinical trials for Haduvio, we're anticipating a year that's rich in data. For Trevi, the road ahead looks exciting, and our focus is firmly fixed on carrying out high-quality trials on schedule. In the coming couple of months, we'll be taking part in a number of investor conferences, which are listed in our press release, and we hope to see plenty of you at them. Thanks for being on today's call, and once it wraps up, we'll be around to answer any follow-up questions you might have.
Operator
operatorThat brings us to the end of this call. We appreciate everyone joining us for today's presentation. You're welcome to log off at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.